Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2021 | Risk stratification for CTCL

Lauren Pinter-Brown • 27 Aug 2021
SOHO 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases

Lauren Pinter-Brown, MD, of UCI Health, Chao Family Comprehensive Cancer Center, Orange, CA, discusses the debate around risk stratification for cutaneous T-cell lymphoma (CTCL) based on the diagnosis, the stage of disease, and other presentations of the disease, as well as existing prototype registries including PROCLIPI. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

More from Lauren Pinter-Brown

1:16
Treatment of advanced CTCL in 2021
Lauren Pinter-Brown • 27 Aug 2021
1:53
Improving clinical knowledge of CTCL
Lauren Pinter-Brown • 27 Aug 2021
1:24
CTCL management: the challenges faced by clinicians
Lauren Pinter-Brown • 27 Aug 2021
1:45
The evolution of CTCL treatment
Lauren Pinter-Brown • 27 Aug 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals